Lyon (France), June 6, 2017 Valneva SE (Valneva or the Group), a biotechnology company dedicated to the development, production and marketing of vaccines and innovative announced today that its President, Thomas Lingelbach has been invited to present Valneva Thursday, June 8th at 10: 30am EDT in New York at the conference Global Healthcare 2017 Jefferies.
Download the free guide
Boost your gains
In addition to this presentation, the President of Valneva will meet with investors attending the conference. Valneva is committed to regular exchange with the financial community. Any information on the Group’s business, such as its financial results and presentations are available on the website of Valneva in the section “Investors & Media” (http://www.valneva.com/en/investors-media/123).
About Valneva SE
Valneva is a biotechnology company specializing in the development, production and marketing of vaccines and innovative.
Valneva strives to generate value through targeted investment in R&D on candidates promising products and growth of the financial contribution of its commercial products.
The product portfolio of Valneva includes two vaccinations of the traveller, IXIARO®/JESPECT® against japanese encephalitis and DUKORAL® in the prevention of cholera, and, in some countries, diarrhea caused by ETEC. The group is also the owner of new vaccines in development against Clostridium difficile, and Lyme disease. Various partnerships with major pharmaceutical companies, mainly focusing on vaccines, current on the development of novel technology platforms of Valneva (the EB66® cell line, the adjuvant IC31® ), will strengthen the value proposition of the group.
The shares of Valneva are traded on Euronext-Paris, the Vienna stock exchange and on the electronic platform Xetra® of the German stock exchange. The group has over 400 employees and operates from France, Austria, Great Britain, Sweden, Canada and the United States. For more information, visit the website of the company www.valneva.com.
Download the free guide
Boost your gains
